New diabetes pill HRS9531 enters phase 2 trial – could it help control blood sugar?
NCT ID NCT07599410
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This study tests whether HRS9531 tablets can safely lower blood sugar in adults with type 2 diabetes who haven't been helped enough by diet, exercise, or metformin alone. About 240 participants will receive either the drug or a placebo for 20 weeks. The main goal is to see if HRS9531 reduces HbA1c, a key measure of long-term blood sugar control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Chaoyang Hospital, Capital Medical University
Beijing, Beijing Municipality, 100020, China
Contact
-
Qilu Hospital of Shandong University
Jinan, Shandong, 250012, China
Contact
Conditions
Explore the condition pages connected to this study.